Drug intelligence / Profile preview

nilofabicin

Development stage: Phase 2
Lead developer: CG Invites
Modality: Small Molecules
Administration: Oral

Overview

Nilofabicin (CG-400549) is an investigational small molecule antibiotic developed as a first-in-class inhibitor of the bacterial enzyme enoyl-acyl carrier protein reductase (FabI), which is essential for fatty acid biosynthesis in bacteria. It exhibits potent activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA), with demonstrated efficacy in both in vitro and in vivo models. Nilofabicin has been studied primarily for the treatment of complicated acute bacterial skin and skin structure infections (cABSSSI) caused by drug-resistant bacteria such as MRSA[1][4][5].

Brand names: nilofabicin
Other names: 1-[(3-amino-2-methylphenyl)methyl]-4-[2-(thiophen-2-yl)ethoxy]-1,2-dihydropyridin-2-one

Targets

InhA

Beyond the preview

Go deeper on nilofabicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nilofabicin.

Explore the full profile